The collapse of Shenzhen-based Jereh, a gold trading platform that operated with massive leverage and no physical backing, has left a trail of financial devastation for 150,000 retail investors, who now confront a controversial repayment plan offering mere fractions of their investments.
Three executive members of a Northern Arizona University fraternity have been charged with hazing after an 18-year-old student died during an off-campus rush event, prompting a university suspension and renewed scrutiny of Greek life practices.
Idorsia's exclusive licensing agreement with EMS to commercialize insomnia drug QUVIVIQ across Latin America marks a key step in its global expansion. The deal, involving $20 million in milestones and royalties, arrives as long-term data for its Fabry disease candidate lucerastat puts the spotlight on the company's broader late-stage pipeline and persistent financial pressures.
After two punishing years, GitLab's shares have been battered by fears over AI's impact on coding. But with a strategic pivot to an AI-powered development platform and a resilient business model, 2026 could be the year the company turns the narrative around.
Oracle's deepening role as TikTok's U.S. data guardian and its aggressive push into regulated AI sectors present a dual narrative of strategic growth and heightened operational scrutiny, following a service outage linked to its infrastructure.
A Goodyear, Arizona woman's attempt to fix her TV's closed captioning spiraled into a six-month ordeal, culminating in the loss of her life savings. This case highlights the sophisticated tactics of modern fraudsters and a dramatic surge in high-dollar scams targeting older adults.
As the Federal Reserve signals potential rate cuts, income-focused investors are re-evaluating their portfolios. We analyze seven dividend ETFs that offer resilient income streams and capital appreciation potential when bond yields decline.
Despite posting strong Q1 results and reaffirming its double-digit growth outlook for fiscal 2026, Intuit's stock has been caught in a broader software sector sell-off. Investors are grappling with whether AI poses a disruptive threat or a tangible growth catalyst for the financial software giant.
Generating cash is just the first step. We analyze three companies to see which ones effectively convert that cash into lasting shareholder value and which ones struggle to capitalize on their financial strength.
While low-volatility stocks can anchor a portfolio, investors often sacrifice growth for stability. We analyze three such stocks, identifying one with resilient fundamentals and two where caution may be warranted.
While robust cash generation is a hallmark of a healthy business, it doesn't automatically translate to a sound investment. We examine three companies with strong free cash flow margins where valuation and strategic concerns give investors pause.
Pharmaceutical giant Eli Lilly announces a massive $3.5 billion investment in a new Pennsylvania manufacturing facility, aiming to scale up production of its blockbuster weight-loss therapies like retatrutide amid soaring global demand.
Thermo Fisher Scientific posted stronger-than-expected Q4 revenue and profit, driven by new products and strategic deals. However, the stock fell as investors weighed pressures in key academic and government markets against the company's solid 2026 outlook.
Robust cash generation is a hallmark of financial health, but it doesn't guarantee future performance. We examine three companies with strong free cash flow margins whose underlying challenges—from competitive pressures to growth concerns—suggest investors should look closer before buying.
Profitability alone is no longer a reliable indicator of future success. In today's competitive landscape, companies must balance healthy margins with sustainable growth. We analyze one firm positioned to do just that, and two where investors should look deeper.
The third-quarter earnings season reveals a sector at a crossroads. While government and technical consulting firms like Jacobs Solutions benefit from long-term structural trends, their latest financial results and market reactions paint a complex picture of resilience and recalibration.
A new report reveals a staggering 67% of purchased sales software features go unused, spotlighting a critical disconnect between tech spending and revenue impact. As IT budgets swell, C-suite leaders are urged to shift from measuring adoption to calculating true dollar-for-dollar returns.
Eli Lilly announces a massive new manufacturing facility in Pennsylvania, part of a strategic pivot by major drugmakers to onshore production amid trade tensions and soaring demand for weight-loss drugs.
Despite lagging the broader market over the past year, Ingersoll Rand shows signs of a strategic pivot. Wall Street sees modest upside potential as the industrial giant navigates headwinds and pursues growth through acquisition.
French biopharma firm Inventiva (ENXTPA:IVA) has delivered a stunning 126% total return to shareholders over the past year, sharply contrasting with losses over a three-year horizon. As the stock experiences short-term pullbacks, analysts debate whether its current €5.23 price reflects future promise or present hype, with a key drug candidate hanging in the balance.
